Doctoral School in Life

and

Health Sciences

PhD Programme in Experimental Medicine and Therapy

Coordinatore: Prof. Giuseppe Poli     

 The main purpose of the PhD program in Experimental Medicine and Therapy is to prepare all students to engage in the analysis and integration of educational theory and experimental practice for an increasingly complex, competitive and modern research in Medicine.

Theoretical and experimental practical training will mainly focus on the following fields:

• Molecular Pathology
• Experimental and Clinical Oncology
• Pathophysiology of the Cardiovascular System
• Metabolic Pathophysiology
• Pathophysiology of the Odontostomatological System
• Experimental Pharmacology and Therapy

Within the frame of the National Research Plan of the Italian Government and the Horizon 2020 Programme for Research and Innovation.

 

 To achieve the given targets and to characterize and suitably integrate the scientific research activity promoted by the PhD programme, the strategy adopted is to support:

1)      topics of common interest for all the involved scientific areas;

2)      knowledge and practice of advanced and complex technologies;

3)      individual and group addressing to the prominent topics of the scientific area in which the PhD Programme teachers and tutors work, and to the relevant professional perspectives.

 

The topics of common interest for all educational activities are:

• inflammation and progression of disease processes;

• oxidative stress and inflammation;

• normal and pathological cell signals involved in cell function, proliferation and death;

• experimental models of protection against multiphasic disease processes promoted by inflammation, infections, toxic and degenerative adverse reactions, altered hormonal responses (tumors, atherosclerosis, myocardial damage, diabetes, Parkinson’s and Alzheimer’s diseases);

• “molecular signaling” pharmacology and therapy directed to the treatment of solid and hemolymphopoietic tumors, cardiovascular and metabolic diseases, degenerative diseases (in connection with pharmaceutical industries).

 

The advanced and complex technologies employed are:

• molecular imaging of: atherosclerosis, myocardial dysfunction, chronic inflammation of the liver, pancreas, intestine, brain and oral cavity;

• employment of human staminal cells obtained from dental pulp, hemopoietic bone marrow and adipose tissue, and differentiated into myocardial, neuronal, hepatocyte and osteoblastic lineages;

• design, production and in vitro and in vivo experimental assay of nanoparticles for the delivering of cell signal modulators and anti-inflammatory, anti-viral, anti-oxidant drugs (in connection with spin off companies, technological platforms and pharmaceutical industries).